Molecular basis for the treatment of renal cell carcinoma

• Autores: Cristina Suárez, Rafael Morales Barrera, Eva Muñoz Couselo, Jordi Rodón, Claudia M. Valverde, Joan Carles Galcerán
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 12, Nº. 1, 2010, págs. 15-21
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Renal cell carcinoma (RCC) is a heterogeneous malignancy whose incidence rate han notably increased in recent years without any evident reason. Traditionally, RCC has been resistant to classic treatments (chemotherapy, radiotherapy and hormonal therapy), with ony a small percentage of patients benefiting from cytokine therapy. Different hereditary syndromes have been associated with RCC, Von Hippel Lindau (VHL) being the most important syndrome. Understanding key molecular pathways implicated in the tumorigenesis of RCC has crystallised in the devolpment of more effective therapies. Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.